Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Up 156.9% in June

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 455,197 shares, an increase of 156.9% from the June 15th total of 177,209 shares. Based on an average daily volume of 444,373 shares, the short-interest ratio is presently 1.0 days. Currently, 46.8% of the shares of the company are sold short.

Bluejay Diagnostics Stock Down 15.9%

Shares of NASDAQ:BJDX opened at $1.22 on Tuesday. The company has a 50-day moving average price of $2.68 and a two-hundred day moving average price of $2.48. Bluejay Diagnostics has a twelve month low of $1.03 and a twelve month high of $16.68. The firm has a market capitalization of $1.26 million, a PE ratio of -0.10 and a beta of 0.88.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

Insider Activity

In related news, major shareholder Financial Lp Hrt sold 34,938 shares of Bluejay Diagnostics stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $1.40, for a total value of $48,913.20. Following the sale, the insider owned 92,055 shares of the company’s stock, valued at approximately $128,877. The trade was a 27.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.